Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
A Phase II Study of Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
Sponsor: Jiangsu Cancer Institute & Hospital
Listed as NCT03126071, this PHASE2 trial focuses on Advanced Colorectal Cancer and remains ongoing. Sponsored by Jiangsu Cancer Institute & Hospital, it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Sep 2021 — Sep 2023 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jul 2018 — Jul 2020 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jul 2018 [monthly]
Recruiting PHASE2
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Cancer Institute & Hospital
For direct contact, visit the study record on ClinicalTrials.gov .